Antipsychotics Flashcards

1
Q

What are the mechanisms of antipsychotics?

A

Mesolimbic Tract – blockade of dopamine receptors here likely is the common MOA
* Overactivity in this region is responsible for positive symptoms of schizophrenia

Mesocortical (MC) Tract – blockade causes negative symptoms
* Responsible for higher order thinking and executive functions

Nigrostriatal (NS) Tract – blockade causes Extrapyramidal SEs (EPSE)
* Modulates body movement

Tuberoinfundibular Tract – blockade leads to hyperprolactinemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the typical antipsychotics?

A

Chlorpromazine, Haloperidol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the differences between chlorpromazine and haloperidol?

A

Both have a1 blockade, resulting in postural hypotension, dizziness

Haloperidol doesn’t have H1 receptor activity unlike chlorpromazine - won’t have the sedation, weight gain

Haloperidol also doesn’t have M1 receptor activity unlike chlorpromazine - won’t have dry mouth, constipation, blur vision

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What do typical antipsychotics do?

A

Control positive symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the atypical antipsychotics?

A

Amisulpride, Clozapine, Olanzapine, Risperidone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What do the atypical antipsychotics do?

A

Control positive symptoms of schizophrenia, but produce less extrapyramidal side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the dopamine blockade points of Clozapine?

A
  • Potent 5-HT2A receptor antagonism vs weak D2 antagonism → lower EPS and higher efficacy against negative symptoms
  • High D4:D2 antagonism → favours action in prefrontal cortex over striatum
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the dopamine blockade points of olanzapine?

A

Potent 5-HT2A receptor antagonism vs weak D2 antagonism → lower EPS and higher efficacy against negative symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the dopamine blockade points of amisulpride?

A

Few side effects due to selectivity for D2/D3 receptors

High D2:D1 reduces impact of antagonism in striatum

High D3:D2 antagonism favours action on nucleus accumbens over striatum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the dopamine blockade points of risperidone?

A

High D2:D1 reduces impact of antagonism in striatum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the side effect profile of amisulpride?

A

Absence of α1-adrenoreceptor block, antihistaminergic and anticholinergic side effects

Has adverse effects on mammary glands & tissues – D2/D3 in tuberoinfundibular pathway
* Increased prolactin secretion due to dopamine receptor block in anterior pituitary gland
* Breast swelling, pain, lactation; Presents as gynecomastia in males

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the precautions for using antipsychotics?

A

CVD – see doctor if you experience any unexplained chest pain
→ QTc prolongation – contraindicated
→ ECG required esp if physical exam identifies CV risk factors, or if there is personal Hx of CVD, or if patient is being admitted and naïve to antipsychotics

Parkinson’s disease – antipsychotics may worsen EPSE

Epilepsy and conditions predisposing to seizures

Depression

Myasthenia gravis

Prostatic hypertrophy

Angle-closure glaucoma

Severe respiratory disease

Hx of jaundice

Blood dyscrasias (esp clozapine)

Elderly w dementia – inc mortality and stroke risks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the steps in the schizophrenia treatment algorithm?

A
  1. Use a single 1st or 2nd generation antipsychotic (except clozapine)
  2. Try a 2nd one if inadequate or no response
  3. Try clozapine if inadequate or no response (routine blood tests for agranulocytosis required)
  4. Add/Replace w antipsychotics or ECT if still inadequate or no response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the criteria for being considered a non-responder to an antipsychotic agent?

A
  • Compliance to an adequate trial of at least 2-6 weeks
  • Must be at optimal therapeutic dose
  • Clozapine: up to 3 months, addition of augmenting agent 8-10 weeks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the antipsychotic options for non-compliant patients?

A

Long-acting injectables eg IM risperidone microspheres, IM aripiprazole LAI, IM haloperidol decanoate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the options to treat acute agitation for cooperative patients?

A

PO lorazepam 1-2mg OR
PO antipsychotic options
→ Haloperidol (tab/solution) 2-5mg with pre-treatment ECG
→ Risperidone (tab/orodispersible/solution) 1-2mg
→ Quetiapine (immediate release tab) 50-100mg
→ Olanzapine (orodispersible tab) 5-10mg

17
Q

What are the options to treat acute agitation for uncooperative patients?

A

IM lorazepam 1-2mg

IM olanzapine 5-10mg – must not be given within 1h of lorazepam
→ 2nd dose ≥2h after 1st dose, 3rd dose ≥4h after 2nd dose

IM aripiprazole (immediate release) 9.75mg (less hypotensive than IM olanzapine)

IM haloperidol 2.5-10mg w pre-treatment ECG

IM promethazine 25-50mg

Haloperidol and Promethazine can be given in combination

18
Q

What are the options to treat catatonia?

A

PO/IM lorazepam

19
Q

What are the treatment options for depressive Sx or negative Sx of chronic schizophrenia?

A

use antidepressants - eg SSRI, SNRI, mirtazapine

20
Q

What are the general monitoring requirements for antipsychotics?

A

Weight gain - monitor BMI Q1/52 for 1st 6 weeks, or every visit (at least Q1/12 for 3/12 for SGA)
Q3/12 when dose stabilized

DM - monitor FBG or HbA1c:
Low risk: annual
High risk: 4/12 after initiating new AP (3/12 if SGA) then annually

Hyperlipidemia - monitor lipid panel
Low risk: every 2-5 years
High risk: Q6/12 (SGA: 1st check at 3/12)

Hyperprolactinemia - monitor plasma prolactin at baseline

BP - monitor 3/12, after initiating SGA then annually

EPSE - do EPSE exam weekly for 1st 2/52 after initiation of new AP or until dose stabilized
1st gen AP: Q6/12 for low risk, Q3/12 for high risk
2nd gen AP: Q12/12 for all risk levels

21
Q

What are the drug specific monitoring requirements?

A

Clozapine (leukopenia/agranulocytosis) - monitor WBC and ANC weekly for 1st 18/52, then monthly

Ziprasidone (QTc prolongation) - Repeat ECG if risks/symptoms of QTc prolongation

22
Q

How does acute dystonia present?

A

→ Occur within 1st few weeks of treatment, but is reversible
→ Parkinsonism-like syndrome eg cogwheel rigidity and tremor at rest

23
Q

What is the cause of acute dystonia in schizophrenia treatment?

A

D2 antagonism in nigrostriatal pathway (connection of substantia nigra to striatum)

24
Q

What is tardive dyskinesia?

A

→ Tardive – develop slowly (eg months-years of treatment)
→ Dyskinesia – repetitive and stereotyped involuntary movements of face, tongue, limbs

25
What is akathisia?
- involuntary movements & compulsion to act, assoc w restlessness, anxiety, agitation - correlated directly during medication duration
26
Why can antipsychotics cause tardive dyskinesia and akathisia?
Likely due to upregulation or supersensitivity of dopamine receptors in nigrostriatal system
27
What are the considerations for treating pregnant women with schizophrenia?
Watch for gestational diabetes if taking olanzapine, clozapine
28
What are the considerations in treating breastfeeding women with schizophrenia?
Olanzapine, quetiapine suitable Clozapine: patients should continue drug if already started, don’t breastfeed
29
What are the considerations in treating schizophrenic patients with renal impairment?
PO aripiprazole preferred, avoid sulpride and amisulpride
30
What are the considerations in treating schizophrenic patients with hepatic impairment?
sulpride, amisulpride preferred
31
What are the considerations in treating elderly with schizophrenia
- Avoid drugs with high propensity for α1-adrenergic blockade (orthostatic hypotension) or anticholinergic side effects (constipation, urinary retention, delirium) - Start low go slow, simplify regimen when possible - Avoid adverse interactions, long T1/2 drugs - FGAs and SGAs reported to inc mortality and stroke in dementia patients
32
How should therapeutic outcomes of schizophrenia be monitored?
Effectiveness – Mental State Exam, Psychiatric Rating Scales Adverse Effect – metabolic parameters (fasting plasma glucose, lipids, BW, BP etc), EPSE Patient’s self-assessment Time course of treatment response: Early improvement → 1st week: dec agitation, aggression, hostility → 2-4 weeks: dec paranoia, hallucinations, bizarre behaviours; improved organisation in thinking Late improvement → 6-12 weeks: dec delusions, negative Sx → 3-6 months: cognitive Sx may improve w SGAs